• Nextleaf (OILS) is launching its new CBD 3:1 vape under the Glacial Gold brand
  • The Glacial Gold CBD 3:1 vape is launching as a 1-gram format in the company’s Berry Lemonade flavour
  • The company expects the Glacial Gold CBD 3:1 Vape to be available first in British Columbia this summer, and nationally through medical cannabis distribution partners
  • Nextleaf Solutions Ltd. (OILS) opened trading at $0.075

Nextleaf (OILS) is introducing its new CBD 3:1 vape under the Glacial Gold brand.

The Glacial Gold CBD 3:1 vape is launching as a 1-gram format in the company’s Berry Lemonade flavour and offers an additional tier of potency at the accessible price point and quality.

The company expects the Glacial Gold CBD 3:1 Vape to be available in British Columbia this summer and nationally through medical cannabis distribution partners.

Glacial Gold CBD products are manufactured using Canadian hemp flower processed at Nextleaf Labs in Greater Vancouver, B.C.

Nextleaf Co-Founder and CEO Paul Pedersen stated that this new vape product fills a gap for consumers looking for a CBD vape that doesn’t crystalize and clog like many of the vapes on the market.

“With Nextleaf’s multi-patented extraction and distillation technology, we are able to control the quality and price of cannabinoid ingredients and position the Glacial Gold brand as a price-point value leader in all distillate-focused product categories.”

Nextleaf is a federally regulated manufacturer and distributor of cannabis vapes and oils under its prohibition-era brand, Glacial Gold.

Nextleaf Solutions Ltd. (OILS) opened trading at $0.075.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.